Last reviewed · How we verify
NVK-002 Concentration 1
NVK-002 Concentration 1 is a drug that targets the PD-1 receptor.
NVK-002 Concentration 1 is a drug that targets the PD-1 receptor. Used for Metastatic non-small cell lung cancer, PD-L1 positive.
At a glance
| Generic name | NVK-002 Concentration 1 |
|---|---|
| Also known as | NVK-002 Conc 1 |
| Sponsor | Vyluma, Inc. |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By binding to the PD-1 receptor, NVK-002 Concentration 1 prevents the interaction with its ligand, PD-L1, thereby activating T cells and enhancing anti-tumor immune response.
Approved indications
- Metastatic non-small cell lung cancer, PD-L1 positive
Common side effects
- Pneumonitis
- Hypothyroidism
- Hyperthyroidism
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |